111 Speen Street, Suite 306
At Alzheon, we apply a precision medicine approach utilizing our scientific knowledge and clinical expertise to make advances in the challenging field of therapeutics for Alzheimer’s and other neurological disorders. Our efforts have resulted in ALZ-801, a novel, investigational medicine with an ideal profile for Alzheimer’s patients: an oral pill with favorable safety and the ability to interfere with the amyloid pathology that leads to Alzheimer’s disease.
95 articles with Alzheon
Mr. Flanzraich was an early investor in Alzheon and served in the role of Chief Business Officer of Alzheon as a consultant to the company from February to May 2018.
8/6/2018Scientists with Framingham, Massachusetts-based Alzheon identified a substance in the human brain that inhibits the formation of beta-amyloid, the primary driver of Alzheimer’s disease. The substance is 3-sulfopropanoic acid (3-SPA).
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801
Presentation at the Alzheimer’s Association International Conference Details Patient Responder Analyses on Key Clinical Outcomes.
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
Keynote at Drug Discovery Innovation Programme and Company Presentation at JMP Securities Life Sciences Conference
5/1/2018Biopharmaceutical companies are focusing their drugs for smaller and smaller and more clearly delineated patient populations. No longer is a drug for lung cancer or even non-small cell lung cancer, but a much smaller segment.
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
Alzheon is offering 5,000,000 shares of its common stock at an initial public offering price between $13.00 and $15.00 per share.
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease
The oral presentation reviews the central role of toxic beta amyloid (Aβ) oligomers in the development and progression of AD.
FDA Grants Fast Track Designation to Alzheon's ALZ-801 Development Program for the Treatment of Alzheimer's Disease
Alzheon announced that FDA has granted Fast Track designation to its lead clinical investigational drug, ALZ-801, for the treatment of Alzheimer’s disease.
Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease
Alzheon announced the publication of clinical results demonstrating that ALZ-801 achieved levels of therapeutic efficacy with favorable safety and tolerability profile for use as an orally-administered medicine for the treatment of Alzheimer's disease (AD).
Alzheon To Make Presentations On ALZ-801 And Its Anti-Oligomer Mechanism At The 10th Clinical Trials On Alzheimer’s Disease Congress
Alzheon Presents New Data For Lead Candidate ALZ-801 On Novel MOA And Long-Term Clinical Efficacy At The Alzheimer’s Association International Conference
Alzheon To Present Novel Molecular Mechanism Of Action And Long Term Clinical Efficacy Data For Lead Candidate ALZ-801 At The Alzheimer’s Association International Conference
Alzheon Publishes New Analyses Showing Clinical Benefit Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification And Align With Beta Amyloid Oligomer Formation
Alzheon Scientists Discover Novel Therapeutic Mechanism Of Inhibition Of Formation Of Toxic Beta Amyloid Oligomers, Key Driver Of Alzheimer’s Disease Pathogenesis
Alzheon Presents Data To Support Selection Of Patients With Mild Alzheimer’s Disease For Pivotal Study Of ALZ-801 Using Precision Medicine Approach
Alzheon To Present New Clinical Data And Analyses For ALZ-801 And Its Active Molecule Tramiprosate At The 13th International Conference On Alzheimer’s And Parkinson’s Diseases